Source: Heart Future; Editor: Sophia
Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.
Recently,Abbott (NYSE: ABT)Announced, itsThe World's FirstDual-chamber Leadless Pacemaker SystemAveir DR Receives CE Mark。This CE approval for Abbott also meansAbout to Enter the European Market, further promoting its Aveir DR Dual-Chamber Leadless Pacemaker System.
In July 2023, Abbott announced its dual-chamber leadless pacemaker systemAveir DR Approved by FDA, and in November of the same yearComplete the First U.S. Commercial ApplicationCase.
# World's First Dual-Chamber Wireless PacemakerAveir DR isThe World's FirstDual-chamber Wireless Pacemaker, consisting of two parts: Aveir VR and Aveir AR. Aveir VR is specifically for the right ventricle, and Aveir AR is specifically for the right atrium, bothAdopted Abbott's i2i (implant-to-implant) communication technology。
Product features of Aveir DR are as follows:Adopting i2i communication technology:It is Abbott's proprietary connected technology, which usesHigh-frequency pulse, leveraging the natural electrical conductivity of blood within the body to transmit signals,Enables two leadless pacemakers to connect with each other, achieving synchronized and coordinated cardiac pacing between the two leadless pacemakers.To support dual-chamber therapy, both implants communicate beat-by-beat with the paired co-implant device.
Lightweight and Energy-saving:According to official disclosure,Aveir DR is only one-tenth the size of a traditional pacemaker., equivalent to an AAA battery, the deviceConnected to the inner surface of the heart through a helical mechanism (referred to as a helix), if treatment needs change or if it is necessary to replace the device in the future, the device can be retrieved.Moreover, the battery current used by this pacemaker is lower than that used for induction, radio frequency or Bluetooth communication, and conductive communication.More energy-efficient。
Reduce the Risk of Complications:Aveir DR Pacing System FeaturesSmall size, lightweightThe advantages are that the implantation procedure is simple, minimally invasive, with a short operation time, and does not require making a pocket or implanting leads.Avoided the risk of pacemaker pocket rupture, infection, lead abrasion and fracture.In addition, Abbott has also developed a dedicatedAveir Delivery and Retrieval Catheter, which is a steerable delivery catheter with a deflection mechanism. The unique triple-loop snare structure can be assembled with Aveir, as shown in the figure below:
# Competitive Product Information- Medtronic —— Wireless Pacemaker Micra
Medtronic'sMicra isThe World's Smallest Heart Pacemaker Currently, only the size of a capsule, with a volume smaller than that of a traditional pacemaker
Reduced by 93%
`, Weight`
Only about 2 grams
。
Compatible with 1.5T/3.0T
Full-body MRI scans provide stable vital energy for patients with arrhythmia.
Advantages of the Micra Leadless Pacemaker:1. Traditional pacemakers leave a noticeable incision and scar on the anterior chest (commonly the left anterior chest), with a larger wound, leading to slower recovery for elderly patients.After Micra Leadless Pacemaker ImplantationNo scars or incisions, and no limitation in movement, significantly improving the patient's quality of life.2. Traditional pacemakers may cause lung injury, leading to problems such as pneumothorax during venipuncture, and the difficulty of puncture increases in elderly patients due to their relatively poor vascular condition.Micra Leadless PacemakerEntering from the femoral vein avoids the above conditions and prevents pocket-related and lead-related complications.3. Traditional pacemakers require 6-12 hours of bed rest after surgery, and the limb on the implanted side should avoid strenuous activities for 3 months.
Micra Leadless Pacemaker CanReduce postoperative recovery time, allowing patients to get out of bed and move around as early as 6 hours after surgery or even sooner.4.Micra has a powerful battery life,Expected service life of 12.8 years, with innovative features such as compatibility with 1.5T/3.0T full-body MRI scans.Micra has two models —— Micra VR (single-chamber) and Micra AV (dual-chamber).
，Approved for marketing by the FDA in 2016 and 2020, respectively.。
In November 2019, Micra VR was officially launched in China.
, minimally invasive surgical treatment for arrhythmia in clinical application.
In May 2022, the new generation Micra AV also received approval from NMPA and officially launched in China.
Medtronic's Micra system has currently evolved to include the Micra VR, Micra AV, Micra AV2, and Micra VR2.
The Latest GenerationMicra AV2 and Micra VR2InApproved by the FDA for marketing in May 2023, on
Received European CE Mark Certification in January 2024。Boston Scientific —— mCRM SystemmCRM System isBoston Scientific's First Leadless Pacemaker, consisting of two cardiac rhythm management (CRM) devices:Emblem MRI Subcutaneous Implantable Defibrillator (S-ICD) System and Empower Modular Pacing System (MPS)。The product is still under development and has not been launched yet.。It is reported that Emblem S-ICD isThe Only Extrathoracic Implantable Defibrillator, the lead does not pass through the cavity, which can prevent sudden cardiac death and risks and complications associated with transvenous leads.Empower Wireless Pacemaker is specificallyDesigned to pair with the S-ICD to deliver pacing or ATP therapy when needed.
Boston Scientific Corporation has announced a study at the Heart Rhythm 2024 conference regardingmCRM Clinical Research Data (APPRAISE ATP)`, the results showed`The study met the pre-specified six-month safety and efficacy endpoints.。
According to statistics, in the global market for cardiac pacemakers,Medtronic, Abbott, and Boston Scientific rank as the top three, collectively accounting for 84.5% of the market share.。JPMorgan Chase analyst Robbie Marcus once said in a research report that Abbott's new productAveir DR will be the first true dual-chamber option, which may satisfy 100% of the market share.# Cardiac Pacemaker Market SizeThe global pacemaker market is expected to increase from USD 3.597 billion in 2021 to$4.224 billion by 2030。Source: Frost & Sullivan
In 2021, the scale in the United States was 1.617 billion US dollars.The largest (45.0%) cardiac pacemaker market globally.China Expected to Become the Fastest Growing Market for Pacemakers。Most of the commercially available pacemakers are developed by five multinational companies. The table below provides a comparison of the latest major pacemakers approved in the United States, the European Union, and/or China:
Source: Frost & Sullivan
Abbott (NYSE: ABT) is a global healthcare company founded in 1888, with its headquarters in Chicago, USA. After a century of development, the company has now become a Fortune 500 enterprise with diversified pharmaceutical and nutritional products.
AbbottBusiness spans across more than 160 countries and regions worldwide, with nearly 110,000 employees., with products covering the fields of nutritional products, pharmaceuticals, medical devices, diagnostic instruments, and reagents.
In April 2024, Abbott released its Q1 2024 financial report,Total Revenue: $9.964 Billion(Approximately RMB 72.15 billion), a year-on-year increase of 2.2%, with revenue growth resuming;Net profit of $12.3 billion(Approximately RMB 8.91 billion), a year-on-year decrease of 7%.
AbbottGlobal sales of medical device business in the first quarter reached $4.45 billion, a year-on-year increase of 14.3%.。Sales of diabetes, electrophysiology, neuromodulation, and structural heart businesses all achieved double-digit growth.
Data from various departments:Medical DeviceRevenue of $4.45 billion, up 14.2% year-over-year;In Vitro DiagnosticsRevenue of $2.21 billion, a year-on-year decrease of 17.6%, including a 40% drop in the rapid diagnostics business in the U.S. market;Nutritional ProductsRevenue of $2.06 billion, a year-on-year increase of 5.1%;Mature DrugRevenue of $1.23 billion, a year-on-year increase of 3.1%;Abbott RaisesSales and Earnings Forecast for Full Year 2024: Organic Sales Expected to Grow 8.5% to 10%(Excluding COVID-19 testing).
